 |
|
|
| |
Longer-Term Safety of Maraviroc in Pediatric
Patients With R5 HIV: Follow-up Data From Study A4001031
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
Giaquinto C,1Mawela MP,2Chokephaibulkit K,3Della Negra M,4Mitha IH,5Fourie J,6Fang A,7van der Ryst E,8Valluri SR,7Vourvahis M,7Zhang-Roper R,9Craig C,8McFadyen L,7Clark A,10Heera J7
1University of Padova, Padova, Italy; 2Sefako Makgatho Health Sciences University, Pretoria, South Africa; 3Siriraj Hospital, Mahidol University, Bangkok noi, Bangkok, Thailand; 4Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil; 5Lakeview Hospital, Gauteng, South Africa; 6Medical Centre, Dundee, KwaZulu Natal, South Africa; 7Pfizer Inc, USA and UK; 8The Research Network, UK; 9GlaxoSmithKline, UK; 10ViiV Healthcare, UK
|
| |
|
|
|
|
|
